IDH2 and glioblastoma: Their cellular signaling and also clinical behavior differs from that of IDH-wild-type glioblastoma of other tyrosine kinase receptors, and the existing data suggest a specific ontogenetic origin during tumorigenesis in the astrocytic lineage.